HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 234.07M USD | Liabilities, Current |
| Cash and equivalents | 549.77M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 111.00M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 6.36M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $234.07M | $549.77M | (m) | $111.00M | $6.36M | (m) |
| 2026-03-31 | (m) | $217.34M | $589.40M | (m) | $108.22M | $5.28M | (m) |
| 2025-12-31 | (m) | $252.13M | $752.50M | (m) | $96.79M | $5.36M | (m) |
| 2025-09-30 | (m) | $223.40M | $647.00M | (m) | $100.65M | $6.88M | (m) |
| 2025-06-30 | (m) | $180.13M | $546.05M | (m) | $92.98M | $6.10M | (m) |
| 2025-03-31 | (m) | $175.12M | $489.00M | (m) | $105.97M | $6.38M | (m) |
| 2024-12-31 | (m) | $175.08M | $453.00M | (m) | $83.03M | $7.20M | (m) |
| 2024-09-30 | (m) | $161.28M | $387.37M | (m) | $81.50M | $6.92M | (m) |
| 2024-06-30 | (m) | $146.58M | $317.30M | (m) | $83.16M | $5.64M | (m) |
| 2024-03-31 | (m) | $154.25M | $332.98M | (m) | $79.72M | $5.86M | (m) |
| 2023-12-31 | (m) | $163.78M | $311.66M | (m) | $74.14M | $5.36M | (m) |
| 2023-09-30 | (m) | $112.41M | $324.60M | (m) | $67.26M | $5.09M | (m) |
| 2023-06-30 | (m) | $93.05M | $317.42M | (m) | $63.81M | $4.85M | (m) |
| 2023-03-31 | (m) | $85.36M | $287.96M | (m) | $52.58M | $4.09M | (m) |
| 2022-12-31 | (m) | $78.88M | $243.78M | (m) | $54.74M | $4.30M | (m) |
| 2022-09-30 | (m) | $107.36M | $261.34M | (m) | $55.06M | $3.90M | (m) |
| 2022-06-30 | (m) | $65.76M | $236.53M | (m) | $49.82M | $4.21M | (m) |
| 2022-03-31 | (m) | $56.53M | $224.50M | (m) | $38.13M | $4.60M | (m) |
| 2021-12-31 | (m) | $53.77M | $234.31M | (m) | $34.84M | $4.43M | (m) |
| 2021-09-30 | (m) | $47.62M | $189.70M | (m) | $33.21M | $4.80M | (m) |
| 2021-06-30 | (m) | $36.59M | $159.69M | (m) | $31.20M | $4.95M | (m) |
| 2021-03-31 | (m) | $33.44M | $141.17M | (m) | $23.61M | $4.41M | (m) |
| 2020-12-31 | (m) | $134.54M | $228.63M | (m) | $22.18M | $3.82M | (m) |
| 2020-09-30 | (m) | $31.79M | $221.74M | (m) | $16.33M | $2.31M | (m) |
| 2019-12-31 | (m) | $19.89M | $24.46M | (m) | $4.25M | $1.09M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |